

150 mg 2 to 3 times daily, which resulted in noticeable improvement in diplopia and ptosis.

Ocular findings can occur in myotonia congenita, although they are reported rarely. This is a unique description of a patient with a *CLCN1* gene mutation who presented with fluctuating diplopia, ocular misalignment, and ptosis as initial symptoms of myotonia congenita. This patient's response to mexilitine suggests myotonia of the extraocular muscles as the likely mechanism for her symptoms. MC is an important diagnostic consideration in evaluating patients with fluctuating ocular symptoms.

Karen Odrzywolski, MD

Nicholas E. Johnson, MD

Paul T. Twydell, DO

Department of Neurology, University of Rochester Medical Center, Rochester, New York

1. Trip J, Drost G, Ginjaar HB, Nieman FH, van der Kooij AJ, de Visser M, et al. Redefining the clinical phenotypes of non-dystrophic myotonic syndromes. *J Neurol Neurosurg Psychiatry* 2009;80:647–652.
2. Thomas J, Tarleton J, Baker SK. Recessive *CLCN1* mutation presenting as Thomsen disease. *Muscle Nerve* 2008;38:1515–1517.
3. Chrestian N, Puymirat J, Bouchard JP, Dupré N. Myotonia congenita—a cause of muscle weakness and stiffness. *Nat Clin Pract Neurol* 2006;2:393–399.
4. Spire M, Tilikete C, Habault C, Vial JC, Kodjikian L, Grange JD. Thomsen myotonia congenita and strabismus: recording saccades in myotonic diseases [in French]. *J Fr Ophthalmol* 2006;29:271–280.

Published online 16 August 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/mus.23634

CASE STUDY OF SPORADIC MITOCHONDRIAL DISEASE WITH MYOTONIC DISCHARGES AND OPTIC ATROPHY

A 44-year-old woman presented with a 6-year history of progressive bilateral ptosis and muscle weakness. Family history was unremarkable. Neurological examination revealed decreased visual acuity, bilateral ptosis and restriction of eye movements during upgaze, downgaze, and adduction. Bilateral optic atrophy and normal appearing retinæ were observed (Fig. 1A). She had normal proximal muscle strength and tendon reflexes, and there was no action or percussion myotonia. Cranial and orbital MRI, electrocardiography, echocardiography, routine blood chemistry, hemogram, serum creatine kinase, cerebrospinal fluid (CSF) examination, and serum and CSF lactate:pyruvate ratio were normal. Needle electromyographic (EMG) examination showed myotonic discharges and polyphasic, short duration motor unit potentials with full recruitment (Fig. 1B). Motor and sensory conduction and repetitive nerve stimulation studies were normal. Muscle biopsy of the deltoid muscle showed cytochrome oxidase negative fibers with ragged-red fibers that stained intensely blue with the histochemical reaction for succinate dehydrogenase (Fig. 1C and D).

According to her clinical, EMG, and muscle biopsy findings chronic progressive external ophthalmoplegia (CPEO) was considered as a possible diagnosis. Analysis of *OPA1* and *RRM2B* genes by means of direct sequencing and multiplex ligation-dependent probe amplification (MLPA) analysis

showed normal results. The 3 primary Leber hereditary optic neuropathy (LHON) mutations were excluded. No mtDNA deletion was found in long range polymerase chain reaction and Southern blot studies.

A single pathogenic mutation, c.803 G>C, p.Gly268 Ala heterozygous, was detected in *POLG1*. It was described as pathogenic in the compound heterozygous state with another mutation (recessive pattern of inheritance).^{1–3} Deletions or duplications of the *POLG1* gene were excluded by means of MLPA analysis. In DNA from muscle of the patient, the variant m.16023 C>T was found with a high heteroplasmy rate of 90–95%. This variant was not detected in blood DNA of the patient. The position m.16023 is the first, 5'-terminal nucleotide of the mitochondrial tRNA proline, located in the acceptor stem of the tRNA.⁴ A mutation in this region of the tRNA might perhaps cause disease, as position 1 of the mt-tRNA Pro is a highly conserved nucleotide.⁵

Myotonic discharges may occur with or without clinical myotonia in myotonia congenita, paramyotonia, myotonic dystrophy, polymyositis, acid maltase deficiency (Pompe disease), hyperkalemic periodic paralysis, and myotubular myopathy.⁶ Our patient had neither clinical nor pathological features of these diseases. Therefore, both the ophthalmoplegic myopathy and myotonia could be explained by mitochondrial pathology in our patient. This clinical picture is further complicated by optic atrophy, which is a hallmark of LHON, but not CPEO.

The mitochondrial diseases have clinical variability, and there is poor correlation between genotype and phenotype. For this reason, classification of these diseases is complex.^{7–10} Our patient shows a sequence variant, m.16023C>T, in the highly conserved position 1 of the acceptor stem of the mitochondrial tRNA Pro, but only in muscle DNA, not in blood DNA. Therefore, this variant might be the cause of the symptoms of the patient, but for further conclusions, her family members have to be analyzed.

To date, myotonic discharges in mitochondrial disorders have been reported only in 1 case.¹¹ Our findings provide further evidence that myotonic discharges can be part of the clinical spectrum of mitochondrial disease.

We thank Prof. Dr. Piraye Oflazer for evaluating muscle biopsy and critical discussion; Dr. Rita Horvath for genetic analysis and critical discussion of genetic analysis results; and Prof. Dr. Feza Deymeer for reviewing the English version of this study. This study was presented at the 44th National Neurology Congress in Antalya, Turkey on November 14, 2008, as a poster presentation.

Aysun Soysal, Assist. Prof¹

Burcu Yüksel, MD¹

Birgit Czermin, PhD²

Selcen Aydemir, MD¹

Betül Tuğcu, MD³

Fikret Aysal, MD¹

Baki Arpacı, Assist. Prof¹

¹Department of Neurology, Bakirkoy Research and Training Hospital for Psychiatry, Neurology and Neurosurgery, Istanbul, Turkey

²Medical Genetic Center, Munich, Germany

³Department of Ophthalmology, Bakirkoy Dr. Sadi Konuk Research and Training Hospital, Istanbul, Turkey




FIGURE 1. Fundusoscopic examination, EMG findings and muscle biopsy of the patient. A: Optic atrophy of the right eye. B: Myotonic discharges in the right tibialis anterior muscle. C: Cytochrome oxidase (COX) negative fibers accompanied with ragged-red fibers (RRF). D: The histochemical reaction for succinate dehydrogenase (SDH) stains intensely blue on deltoid muscle biopsy. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]

1. Di Fonzo A, Bordoni A, Crimi M, Sara G, Del Bo, Bresolin N, et al. POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions. *Hum Mutat* 2003;22:498–499.
2. Baruffini E, Lodi T, Dallabona C, Puglisi A, Zeviani M, Ferrero I. Genetic and chemical rescue of the *Saccharomyces cerevisiae* phenotype induced by mitochondrial DNA polymerase mutations associated with progressive external ophthalmoplegia in humans. *Hum Mol Genet* 2006;15:2846–2855.
3. Gonzalez-Vioque E, Blazquez A, Fernandez-Moreira D, Bornstein B, Bautista J, Arpa J, et al. Association of novel POLG mutations and multiple mitochondrial DNA deletions with variable clinical phenotypes in Spanish population. *Arch Neurol* 2006;63:107–111.
4. Pathogenic and polymorphic mutations: <http://mamit-trna.u-strasbg.fr/mutations.asp?idAA=21>; mitoWheel: <http://www.mitowheel.org/mitowheel.html>.
5. Helm M, Brule H, Friede D, Giege R, Puetz D, Florentz C. Search for characteristic structural features of mammalian mitochondrial tRNAs. *RNA* 2000;6:1356–1379.
6. Dumitru D, Amato AA. Introduction to myopathies and muscle tissue's reaction to injury. In: Dumitru D, Amato AA, Zwarts MJ, editors. *Electrodiagnostic medicine*, 2nd edition. Philadelphia: Hanley and Belfus, Inc; 2002. p 1229–1264.
7. Arpa J, Cruz-Martinez A, Campos Y, Gutierrez-Molina M, Garcia-Rio F, Perez-Conde C, et al. Prevalence and progression of mitochondrial diseases: a study of 50 patients. *Muscle Nerve* 2003;28:690–695.
8. Amato AA, Brooke MH. Disorders of skeletal muscle. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic, editors. *Neurology in clinical practice*, 4th edition, Vol 2. Philadelphia: Butterworth-Heinemann; 2004. p 2463–2510.
9. Verma A, Moraes CT. Mitochondrial disorders. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic, editors. *Neurology in clinical practice*, 4th edition, Vol 2. Philadelphia: Butterworth-Heinemann; 2004. p 1833–1845.
10. Finsterer J. Central nervous system manifestations of mitochondrial disorders. *Acta Neurol Scand* 2006;114:217–238.
11. Howse MLP, Wardell TM, Fisher CJ, Tilley PJB, Chinnery PF, Bindoff L. Late-onset mitochondrial disorder with electromyographic evidence of myotonia. *Muscle Nerve* 2003;28:757–759.

Published online 2 October 2012 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/mus.23641